US Pharma MarketingFDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyout
GSK's $10.6 billion acquisition of Nuvalent is delivering surprisingly early results. The FDA on Wednesday approved one of Nuvalent's lung cancer medicines two months earlier than projected, and the biotech still has ...
GSK's $10.6 billion acquisition of Nuvalent is delivering surprisingly early results.
The FDA on Wednesday approved one of Nuvalent's lung cancer medicines two months earlier than projected, and the biotech still has ...
Source: Endpoints News